Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Solarvest Continues To Add Expertise To Its Cannabinoid Active Pharmaceutical Ingredient (API) Program

V.SVS.H

(via TheNewswire)



Vancouver, BC - TheNewswire - September 26th, 2019 - SOLARVEST BIOENERGY INC. (TSXV:SVS) ("Solarvest" or the "Company"), is pleased to announce that Dr. Azoy Kumar Kundu has joined Solarvest's protein expression team. His extensive background includes protein science and in-depth experience in genetic technologies. He worked in a team that was successful in developing and receiving FDA approval for the world's first GMO food animal.

Dr. Kundu's experience will be a significant addition to the team for the ongoing lab work for Solarvest's collaborative program to produce API ("approved pharmaceutical ingredient") cannabinoids utilizing our algal biopharmaceutical platform. Azoy will specifically bring to the team his expertise in the construction of vectors, molecular cloning and DNA manipulation. His experience with GLP, quality assurance, bioassay development, study protocol development, study design, study validation, and study report writing will be vital to ensure regulatory approval of any successful cannabinoid expressed and purified for use as an API.

About Solarvest:

Solarvest BioEnergy Inc. is an algae biotechnology company whose algal-based production platform provides it with an extremely flexible system capable of being adapted to produce numerous products - from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated (news release dated March 16th. 2015) the expression of BMP, a high value therapeutic protein. In addition the company's platform has successfully produced recombinant viral antigens (immune stimulating proteins,) Cecropins (antimicrobial pepetide/protein). The company has initiated a program for the expression of CBD and THC.as a way to produce CBD and THC in sterile bioreactors.

For further information contact:

Garth Greenham, COO Solarvest Bioenergy Inc.

Tel: 416 420 0947 Email: ggreenham@solarvest.ca

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the Company's expectations and projections.

.

Copyright (c) 2019 TheNewswire - All rights reserved.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today